Literature DB >> 31308826

Uterine sarcoma: a clinical case and a literature review.

Diana Bužinskienė1,2, Saulius Mikėnas3,4, Gražina Drąsutienė1,2, Matas Mongirdas5.   

Abstract

BACKGROUND: Uterine sarcomas are rare gynaecologic tumours representing 3-7% of all uterine malignancies. The aetiology of sarcomas is still unclear: it is thought, that chromosomal translocations have influence on wide histological variety of sarcomas. Presenting symptoms are vague and nonspecific. Usually sarcoma causes abnormal vaginal bleeding, can cause abdominal or pelvic pain, or manifests as a rapidly growing uterine tumour. The diagnosis of sarcoma is often made retrospectively after surgical removal of a presumed benign uterine neoplasm, because imaging modalities such as ultrasound, computed tomography, or magnetic resonance imaging cannot yet accurately and reliably distinguish between benign leiomyoma and malignant pathology. If there are certain clinical features that raise a suspicion of malignancy in the uterus, it is recommended to avoid the use of power morcellation through laparoscopic surgery in order to prevent disease dissemination.
MATERIALS AND METHODS: We present a clinical case of a 64-year-old patient, who was referred to hospital due to abdominal pain and tenesmus that lasted for two days. From a past medical history it was known that previously the patient had been diagnosed with uterine myoma. Transvaginal ultrasonography showed a 10.4 cm × 9.8 cm uterine tumour of nonhomogeneous structure with signs of necrosis and good vascularization. The patient refused urgent hysterectomy, that was advised to her. The patient was operated on one month later and total hysterectomy with bilateral salpingooforectomy was performed. Postoperative histological evaluation showed undifferentiated sarcoma uterus pT1b L/V0. Imaging modalities were made to evaluate possible dissemination of the disease. In the absence of signs of disease progression, the patient received radiotherapy and brachytherapy and was followed-up by doctors. RESULTS AND
CONCLUSIONS: Uterine sarcomas are highly malignant tumours that originate from smooth muscles and connective tissue elements of the uterus and make up 1% of all malignant gynaecological tumours and about 3-7% of all malignant uterine tumours. Imaging modalities cannot yet reliably distinguish benign myomas from malignant sarcomas. It is important not to damage the wholeness of uterus during operation in order to prevent dissemination of the disease in the abdominal cavity. The low-grade endometrial stromal sarcoma has the best survival prognosis, while carcinosarcoma and undifferentiated uterine sarcoma have the lowest survival rates.

Entities:  

Keywords:  malignant uterine neoplasm; treatment; undifferentiated uterine sarcoma; uterine sarcoma; uterine sarcoma diagnosis; uterine tumour

Year:  2018        PMID: 31308826      PMCID: PMC6591694          DOI: 10.6001/actamedica.v25i4.3931

Source DB:  PubMed          Journal:  Acta Med Litu        ISSN: 1392-0138


  33 in total

1.  Uterine sarcoma associated with tamoxifen use.

Authors:  Diane K Wysowski; Susan Flamm Honig; Julie Beitz
Journal:  N Engl J Med       Date:  2002-06-06       Impact factor: 91.245

Review 2.  Role, epidemiology, and natural history of benign uterine mass lesions.

Authors:  Ginny L Ryan; Craig H Syrop; Bradley J Van Voorhis
Journal:  Clin Obstet Gynecol       Date:  2005-06       Impact factor: 2.190

3.  Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: An analysis of 26,758 cases.

Authors:  Jorge R Toro; Lois B Travis; Hongyu Julian Wu; Kangmin Zhu; Christopher D M Fletcher; Susan S Devesa
Journal:  Int J Cancer       Date:  2006-12-15       Impact factor: 7.396

4.  Neutrophil to lymphocyte ratio for preoperative diagnosis of uterine sarcomas: a case-matched comparison.

Authors:  H S Kim; K H Han; H H Chung; J W Kim; N H Park; Y S Song; S B Kang
Journal:  Eur J Surg Oncol       Date:  2010-06-08       Impact factor: 4.424

5.  Use of estradiol-progestin therapy associates with increased risk for uterine sarcomas.

Authors:  Susanna Jaakkola; Heli K Lyytinen; Eero Pukkala; Olavi Ylikorkala
Journal:  Gynecol Oncol       Date:  2011-04-30       Impact factor: 5.482

6.  Potential role of preoperative serum CA125 for the differential diagnosis between uterine leiomyoma and uterine leiomyosarcoma.

Authors:  C M Juang; M S Yen; H C Horng; N F Twu; H C Yu; W L Hsu
Journal:  Eur J Gynaecol Oncol       Date:  2006       Impact factor: 0.196

7.  Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients.

Authors:  Vera M Abeler; Odd Røyne; Steinar Thoresen; Håvard E Danielsen; Jahn M Nesland; Gunnar B Kristensen
Journal:  Histopathology       Date:  2009-02       Impact factor: 5.087

Review 8.  Clinical management of uterine sarcomas.

Authors:  Frédéric Amant; An Coosemans; Maria Debiec-Rychter; Dirk Timmerman; Ignace Vergote
Journal:  Lancet Oncol       Date:  2009-12       Impact factor: 41.316

Review 9.  Uterine sarcomas: a review.

Authors:  Emanuela D'Angelo; Jaime Prat
Journal:  Gynecol Oncol       Date:  2009-10-23       Impact factor: 5.482

10.  Can gray-scale and color Doppler sonography differentiate between uterine leiomyosarcoma and leiomyoma?

Authors:  Caterina Exacoustos; Maria Elisabetta Romanini; Annalisa Amadio; Concetta Amoroso; Beata Szabolcs; Errico Zupi; Domenico Arduini
Journal:  J Clin Ultrasound       Date:  2007-10       Impact factor: 0.910

View more
  2 in total

1.  Successful Laparoscopic-Assisted Supracervical Hysterectomy in a 14-Week-Sized Fibroid Uterus: An Autobiographical Case Report.

Authors:  Leah Eburne; Richard J Vagovic
Journal:  Cureus       Date:  2022-01-24

2.  Adjuvant radiotherapy shows benefit in selected stage I uterine sarcoma: A risk scoring system based on a population analysis.

Authors:  Yun-Xia Huang; Yan-Zong Lin; Yi-Min Li; Ke-Xin Chu; Yu-Fei Zhou; Li-Mei Lin; Rui Zhou; Zong-Kai Zhang; Qin Lin
Journal:  Cancer Med       Date:  2022-03-11       Impact factor: 4.711

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.